Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade.

Larroquette, Mathieu; Lefort, Félix; Heraudet, Luc; Bernhard, Jean-Christophe; Ravaud, Alain; Domblides, Charlotte; Gross-Goupil, Marine

Larroquette, Mathieu; Lefort, Félix; Heraudet, Luc; Bernhard, Jean-Christophe; Ravaud, Alain; Domblides, Charlotte; Gross-Goupil, Marine.

Afiliación

Larroquette M; Department of Medical Oncology, University Hospital of Bordeaux, 33000 Bordeaux, France.
Lefort F; Faculty of Medicine, University of Bordeaux, 33000 Bordeaux, France.
Heraudet L; Department of Medical Oncology, University Hospital of Bordeaux, 33000 Bordeaux, France.
Bernhard JC; Department of Medical Oncology, University Hospital of Bordeaux, 33000 Bordeaux, France.
Ravaud A; Faculty of Medicine, University of Bordeaux, 33000 Bordeaux, France.
Domblides C; Faculty of Medicine, University of Bordeaux, 33000 Bordeaux, France.
Gross-Goupil M; Department of Urology, University Hospital of Bordeaux, 33000 Bordeaux, France.

Cancers (Basel) ; 14(24)2022 Dec 17.

Article en En | MEDLINE | ID: mdl-36551715

Palabras clave

VEGF-TKI; checkpoint inhibitor; combination; renal cell carcinoma; strategy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google